According to a new report, published by KBV research, The Global Antiplatelet Market size is expected to reach $5.1 billion by 2030, rising at a market growth of 4.7% CAGR during the forecast period. In the year 2022, the market attained a volume of 430.4 million Units experiencing a growth of 3.4 % (2019-2022).
The Injectable segment is exhibiting a CAGR of 6.6% during (2023 - 2030). Injectable antiplatelet medications are essential to the antiplatelet market, especially in critical care settings, during surgeries, and when oral administration is not feasible or fast enough to achieve the desired effect. Injectable antiplatelet agents are administered intravenously (IV) or subcutaneously (SC) and can provide rapid and potent platelet inhibition. Healthcare providers carefully consider injectable antiplatelet medications based on the patient's clinical condition, the need for rapid platelet inhibition, and the risk of bleeding complications.
The Adenosine diphosphate (ADP) Receptor Inhibitors segment is capturing maximum revenue in the Global Antiplatelet Market by Drug Class in 2022; thereby, achieving a market value of $3.4 Billion by 2030. These drugs target ADP receptors on platelets, which are critical for platelet activation and aggregation. By inhibiting these receptors, ADP receptor inhibitors reduce platelet activation and help prevent the formation of blood clots. Clopidogrel is one of the most widely used ADP receptor inhibitors. It is an oral antiplatelet medication commonly prescribed to lower the risk of strokes, heart attacks, and other cardiovascular events. Clopidogrel irreversibly binds to the P2Y12 ADP receptor on platelets, inhibiting their activation.
The Hospital Pharmacies segment is experiencing a CAGR of 5.1% during (2023 - 2030). Hospital pharmacies are responsible for dispensing antiplatelet medications to patients. This includes providing the correct dosage and formulation of drugs like aspirin, clopidogrel, ticagrelor, and others as prescribed by healthcare providers. Hospital pharmacies ensure that the right patients receive the right antiplatelet medications, helping to minimize medication errors and adverse events. Proper labeling, verification, and protocol adherence are essential in this regard.
The North America region dominated the Global Antiplatelet Market by Region in 2022; thereby, achieving a market value of $2.05 Billion by 2030. The Europe region is anticipated to grow a CAGR of 4.5% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 5.5% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/antiplatelet-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
By Route of Administration (Volume, Million Units, USD Million, 2019-2030)
By Drug Class (Volume, Million Units, USD Million, 2019-2030)
By Distribution Channel (Volume, Million Units, USD Million, 2019-2030)
By Geography (Volume, Million Units, USD Million, 2019-2030)
Companies Profiled
Unique Offerings 
